Ali Tavakoli Pirzaman’s Post

Great work! In the context of cancer therapy, the development of targeted approaches such as PROTAC 13i represents a promising avenue. By selectively degrading key proteins involved in cancer progression, such as CK1α, CDK7, and CDK9, PROTAC 13i holds the potential to reactivate the tumor-suppressive functions of p53. This reactivation of p53-mediated pathways could lead to the elimination of malignant cells, offering new hope for the treatment of acute myeloid leukemia (AML) #РROTAC #AML #drugdiscovery https://lnkd.in/eiTx3mky

🌐 Diagnostics, Volume 13, Issue 2 (January-2 2023) 🔬 THSD7A Positivity Is Associated with High Expression of FAK in Prostate Cancer 🔍 Several studies indicate that THSD7A might play a role at least in the prognosis of different tumor types. FAK, a key player in prostate cancer progression, is being explored as a therapeutic target, particularly in advanced stages. 💡 This research investigates whether THSD7A expression impacts the expression of FAK in its unphosphorylated form. With evidence pointing to THSD7A’s involvement in FAK-dependent pathways, it opens the discussion of THSD7A as a potential therapeutic target in prostate cancer. 📖 Discover more: https://lnkd.in/d9kvcMH3 #THSD7A #FAK #ProstateCancer #Diagnostics

I am thrilled to announce that our article titled “The emerging role of TIM-3 in colorectal cancer: a promising target for immunotherapy” has been published in Expert Opinion on Therapeutic Targets (IF: 4.6, Q1). In our article, we explore the significant role of T cell immunoglobulin-3 (TIM-3) as an immune checkpoint in colorectal cancer (CRC). While TIM-3 is traditionally viewed as a marker of T cell dysfunction, our review reveals its complex involvement in tumor progression and immune evasion. We detail the structural and functional aspects of TIM-3, examining its expression in CRC and the implications for therapeutic strategies. #colorectalcancer #Immunotherapy #TIM3 #ResearchPublication #Oncology #CancerResearch

Research, including randomized controlled trials and meta-analyses, shows that low-dose computed tomography (LDCT) screening significantly reduces mortality from lung cancer. This review, based on the 9th CT Screening Symposium by International Association for the Study of Lung Cancer, highlights essential themes for the global implementation of LDCT screening and offers strategies to expand lung cancer screening worldwide. https://lnkd.in/eiurqKQJ #LungCancer #IASLC #OncoDaily #Oncology #Cancer #Health #Medicine

🔬 Exciting Developments in Cancer Research: Magnolia officinalis in Colorectal Cancer Treatment A groundbreaking study titled "Effect and Mechanism of Magnolia officinalis in Colorectal Cancer: Multi-Component-Multi-Target Approach" sheds light on the anti-cancer potential of Magnolia officinalis in colorectal cancer

Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC Tagrisso (Osimertinib) is a recommended treatment for advanced non–small-cell lung cancer (NSCLC) with an epidermal growth factor receptor (EGFR) mutation and as adjuvant treatment for resected EGFR-mutated NSCLC. Patients with unresectable stage III EGFR-mutated NSCLC have no approved targeted treatments available. In this new trial, treatment with osimertinib resulted in significantly longer progression-free survival than placebo in patients with unresectable stage III EGFR-mutated NSCLC. #Cancer #Oncology #Tagrisso #osimertinib #LungCancer  #NonSmallCellLungCancer #NSCLC #EGFR #Moffitt #MoffittCancerCenter Moffitt Cancer Center

Did you know that June is Cancer Immunotherapy Month? Learn more about anti-bevacizumab antibodies: https://lnkd.in/g2Q8yMWv Bio-Rad offers a range of antibodies to study cancer therapies, such as anti-bevacizumab antibodies targeting bevacizumab, a drug used to treat various cancers, including colorectal, lung, breast, glioblastoma, kidney, and ovarian. #antibodies #cancerresearch #oncology

Exciting new research in the field of bladder cancer! A recent systematic review and meta-analysis delves into the clinicopathological significance of B7-H3, a potential biomarker for prognosis and treatment in bladder cancer. The study uncovers key insights into B7-H3 expression in tumor tissues, patient age, and recurrence. However, the link to overall survival remains uncertain. A must-read for oncology professionals seeking in-depth knowledge of bladder cancer biomarkers. #BladderCancer #B

Few of the positive trials we have data for in LCSM from ASCO24 - GILBERTO de lima LOPES Junior American Society of Clinical Oncology (ASCO) Sylvester Comprehensive Cancer Center University of Miami Miller School of Medicine Union for International Cancer Control (UICC) #ASCO #ASCO24 #Cancer #LungCancer #OncoDaily #Oncology

Our paper on small-molecule #immunomodulators targeting the #CCL20/#CCR6 axis has just been accepted @ChemMedChem. The reduction of CCL20-induced #chemotaxis of human peripheral blood mononuclear cells (PBMC) is also accompanied by a strong #antitumor activity on different colon cancer cell lines. Quite promising data for IBD-associated colorectal cancer #CRC https://lnkd.in/dzaXWqKs